Retail sales of Tylenol remain broadly steady across global markets even as the brand faces mounting political and legal scrutiny.
In recent months, remarks from US President Donald Trump and several of his allies alleging a link between Tylenol use during pregnancy and autism have reignited safety debates surrounding the popular over-the-counter (OTC) pain reliever.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The claims, dismissed by medical experts and regulators, briefly unsettled investors and fuelled online discussion, but early retail indicators suggest limited long-term impact on consumer demand.
Kenvue, Tylenol’s parent company, does not publish brand-specific figures, but analysts estimate annual Tylenol sales at roughly US$1 billion. The brand sits within Kenvue’s Self Care division, which posted organic growth of 1.7 per cent in the final quarter of 2024 and total net sales of US$15.5 billion for the year.
Those results underline continued strength in the company’s OTC portfolio despite reputational turbulence.
Political claims and investor reaction
In September 2025, Trump used a campaign event and social-media posts to suggest that Tylenol could cause autism when taken during pregnancy. The allegations were unsupported by scientific evidence but spread rapidly online, amplified by political commentators and sympathetic media figures.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataShares in Kenvue fell to a record low the following day as retail investors reacted to the headlines before rebounding once analysts and health authorities reaffirmed that no causal link had been established.
For retailers, the episode highlighted how politically driven health narratives can momentarily affect consumer sentiment and brand perception.
Industry analysts noted a brief dip in Nielsen scanner data following the controversy, particularly in the United States, though sales largely normalised within weeks as coverage subsided.
Ongoing lawsuits and safety debate
Beyond the political noise, Kenvue and its former parent Johnson & Johnson face hundreds of lawsuits alleging that prenatal acetaminophen exposure causes neurodevelopmental disorders such as autism and ADHD.
Most scientific reviews, including those referenced by US and European regulators, have found the evidence inconclusive. Nevertheless, the cases continue to generate headlines.
On 28 October 2025, the Texas Attorney General sued both companies, claiming they misled pregnant consumers about potential risks. Kenvue has denied wrongdoing, calling its product safe when used as directed.
Legal experts say the litigation could take years to resolve and is unlikely to lead to immediate product removals, but ongoing attention may shape consumer choices and push some shoppers toward alternatives such as ibuprofen or private-label paracetamol.
Retail trends: resilience amid scrutiny
The broader acetaminophen market remains robust. Valued at over US$10 billion in 2024, it continues to grow steadily, fuelled by global demand for accessible pain relief and the expansion of e-commerce channels.
Online pharmacy sales of paracetamol products have risen sharply since the pandemic, allowing consumers to compare prices and reviews more easily.
This transparency has strengthened generic competition, though Tylenol’s established reputation still secures premium shelf space and high brand recognition.
Retail buyers note that category performance remains tied more to seasonality and consumer convenience than to political or legal headlines. Tylenol’s sustained sales volumes suggest that shoppers continue to trust long-standing OTC brands for mild pain and fever relief, even when public debate intensifies.
Outlook for global retailers
Tylenol’s recent experience underscores the growing interplay between politics, litigation and retail health brands.
High-profile commentary from figures like Trump can cause temporary volatility in share prices and online chatter, but tangible effects on in-store performance appear limited so far. The longer-term risk lies in consumer fatigue and gradual switching to cheaper or “safer-perceived” alternatives if lawsuits or misinformation persist.
For global retailers, the message is twofold: established OTC brands can weather controversy when supported by consistent availability and trust, yet vigilance is essential as public opinion around health products evolves in real time.
Tylenol’s ability to maintain retail momentum amid lawsuits, political claims and a broader safety debate highlights both the resilience and the reputational vulnerability of household healthcare names in today’s hyper-connected market.
Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData’s Strategic Intelligence here.
